Renalytix AI PLC ADR (RNLX) News
Filter RNLX News Items
RNLX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RNLX News Highlights
- For RNLX, its 30 day story count is now at 4.
- Over the past 28 days, the trend for RNLX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest RNLX News From Around the Web
Below are the latest news stories about Renalytix plc that investors may wish to consider to help them evaluate RNLX as an investment opportunity.
KidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of CareData highlights strength of KidneyIntelX for clinical use in early-stage diabetic kidney disease patients beyond commonly used markers UACR and historical eGFR change over timeNEW YORK and SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the presentation of new clinical data for KidneyIntelX™ bioprognostic™ testing at the World Congress of Nephrology Annual Meeting. The results provide robust prognostic information demonstrating the value |
Renalytix to Present at Cowen 42nd Annual Health Care ConferenceNEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42nd Annual Health Care Conference. Renalytix’s management is scheduled to participate in a fireside chat on Wednesday, March 9, 2022, at 10:30 a.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at inv |
Renalytix to Appoint Timothy Scannell to Board of DirectorsNEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell is a distinguished leader in healthcare innovation, who brings more than 30 years of experience from his time at Stryker, one of the world’s leading medical technology companies. During his time as President and C.O.O., Mr. Scannell was responsible for all |
Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Renalytix’s management is scheduled to participate in a fireside chat on Tuesday, February 15, 2022, at 3:30 p.m. EST. Due to the format of this virtual event the presentation will not be webcast. The company will be available f |
Renalytix AI PLC Sponsored ADR (RNLX) Surges 10.4%: Is This an Indication of Further Gains?Renalytix AI PLC Sponsored ADR (RNLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Analysts Are Bullish on Top Technology Stocks: Phreesia (PHR), Renalytix AI (RNLX)There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Phreesia (PHR – Research Report) and Renalytix AI (RNLX – Research Report) with bullish sentiments. Phreesia (PHR) In a report released today, Ryan MacDonald from Needham maintained a Buy rating on Phreesia, with a price target of $65.00. The company's shares closed last Friday at $35.55, close to its 52-week low of $33.65. According to TipRanks. |
Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug TherapyAmerican Journal of Nephrology data demonstrates KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment Study (CANVAS) multinational clinical trial cohort patientsNEW YORK and SALT LAKE CITY, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) announced the publication of positive study results for KidneyIntelX™ as a risk monitoring tool to assess impact and response to novel treatments for patients with diabetes a |
Singing River Health System and Renalytix Join Forces to Improve Kidney Health on the Mississippi Gulf CoastSeventh KidneyIntelX implementation partnership for Renalytix focused on underserved populations with high disease burdenGULF COAST, Miss. and SALT LAKE CITY, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Singing River Health System and Renalytix (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to deploy KidneyIntelX™ informed care management to improve kidney health in individuals with type 2 diabetes and early-stage chronic kidney disease. The Renalytix KidneyIntelX platform enables Singing River’ |
Renalytix Appoints Jean M. Casner as Chief Human Resources OfficerNEW YORK and SALT LAKE CITY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that Jean M. Casner joined the Company this week on January 3, 2022 as Senior Vice President & Chief Human Resources Officer. Ms. Casner will be responsible for Renalytix’s global human resources organization, including people strategy, compensation, benefits, learning and development, diversity & inclusion, and performance and talent management. Ms. Casner joins Renalytix from |
Renalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare ConferenceNEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40th Annual J.P. Morgan Virtual Healthcare Conference. Renalytix’s management is scheduled to present on Wednesday, January 12, 2022, at 2:15 p.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix |